Tetratherix

Tetratherix PEG

The PEG Ratio (Price/Earnings-to-Growth) of Tetratherix (TTX.AX) as of Oct 22, 2026 is -3.20.

PEG

-3.20

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Tetratherix is 2026 -3.20 . PEG Ratio (Price/Earnings-to-Growth) of Tetratherix was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tetratherix Stock analysis

What does Tetratherix do? Tetratherix Ltd. develops a biostealth fluid matrix for regenerative medicine, creating injectable products that form 3D matrices upon physiological temperature exposure. The company's biomaterial platform uses polymer programming for implantable solutions, with Tegenix and TegenEOS serving as carriers mixed with bone graft materials for dental, oral, and orthopedic applications. TetraDerm products address surgical incision sites to minimize scarring, while Tutelix functions as a spacer to mitigate radiation therapy side effects in prostate cancer. The firm's manufacturing center in Sydney handles cleanroom production of these medical solutions. The company's revenue streams come from selling Tegenix, TegenEOS, TetraDerm, and Tutelix products to healthcare providers, hospitals, and medical device distributors specializing in regenerative medicine. These products target clinical segments including dental procedures, orthopedic surgery, and oncology treatments. Tetratherix's injectable fluid matrix technology differentiates its offerings by enabling tissue integration without causing bodily damage during application, supporting its positioning in the regenerative medicine market. Tegenix and TegenEOS are marketed as complementary solutions for bone graft applications, while TetraDerm focuses on post-surgical scar reduction. Tutelix specifically addresses radiation therapy side effects in prostate cancer patients. The company's manufacturing center in Sydney ensures quality production of these medical products, which are distributed to healthcare professionals across dental, orthopedic, and oncology fields. Tetratherix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tetratherix stock

PEG Ratio (Price/Earnings-to-Growth) of Tetratherix is -3.20 in 2026.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Tetratherix since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Tetratherix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tetratherix

All Key Metrics — Tetratherix